StockNews.com Begins Coverage on Oncternal Therapeutics (NASDAQ:ONCT)

Research analysts at StockNews.com initiated coverage on shares of Oncternal Therapeutics (NASDAQ:ONCT) in a report issued on Friday. The brokerage set a “hold” rating on the stock.

A number of other research analysts also recently weighed in on ONCT. Brookline Capital Management reissued a “hold” rating on shares of Oncternal Therapeutics in a research note on Thursday, September 12th. Northland Capmk downgraded Oncternal Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Thursday, September 12th. Finally, Northland Securities restated a “market perform” rating and issued a $2.00 price objective on shares of Oncternal Therapeutics in a research note on Thursday, September 12th. Four equities research analysts have rated the stock with a hold rating and one has assigned a buy rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus price target of $10.00.

Oncternal Therapeutics Price Performance

NASDAQ ONCT opened at $0.53 on Friday. Oncternal Therapeutics has a fifty-two week low of $0.53 and a fifty-two week high of $13.14. The stock’s 50-day moving average is $1.12 and its two-hundred day moving average is $4.01. The firm has a market cap of $1.56 million, a P/E ratio of -0.05 and a beta of 1.18.

Institutional Trading of Oncternal Therapeutics

An institutional investor recently bought a new position in Oncternal Therapeutics stock. Pasadena Private Wealth LLC purchased a new position in shares of Oncternal Therapeutics, Inc. (NASDAQ:ONCT) in the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 25,000 shares of the company’s stock, valued at approximately $190,000. Pasadena Private Wealth LLC owned about 0.84% of Oncternal Therapeutics as of its most recent SEC filing. Institutional investors own 16.05% of the company’s stock.

Oncternal Therapeutics Company Profile

Oncternal Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of oncology therapies for cancers with critical unmet medical needs. The company's clinical pipeline includes zilovertamab, a humanized monoclonal antibody that binds to receptor-tyrosine kinase-like Orphan Receptor 1 (ROR1); and ONCT-216, a small molecule inhibiting the biological activity of ETS-family transcription factor oncoproteins, which is in Phase 1/2 clinical trial.